{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Arzneilisten"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import requests\n",
    "from bs4 import BeautifulSoup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.set_option('display.max_rows', 1000)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Anmerkung</th>\n",
       "      <th>Anwendungsgebiet</th>\n",
       "      <th>Datum</th>\n",
       "      <th>Ergebnis</th>\n",
       "      <th>Wirkstoff</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>A19-52</td>\n",
       "      <td>Erwachsene mit Diabetes mellitus Typ 2</td>\n",
       "      <td>01.10.2019</td>\n",
       "      <td>Zusatznutzen für keine der 3 vom G-BA benannte...</td>\n",
       "      <td>Dapagliflozin/Metformin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>A19-53</td>\n",
       "      <td>Erwachsene mit Diabetes mellitus Typ 2</td>\n",
       "      <td>01.10.2019</td>\n",
       "      <td>Zusatznutzen für keine der 5 vom G-BA benannte...</td>\n",
       "      <td>Dapagliflozin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>A19-61</td>\n",
       "      <td>Erwachsene in der Erstlinientherapie des metas...</td>\n",
       "      <td>19.09.2019</td>\n",
       "      <td>PD-L1-Expression &lt; 50 %: für Frauen Beleg für ...</td>\n",
       "      <td>Pembrolizumab mit Pemetrexed und Platin-Chemot...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>A19-62</td>\n",
       "      <td>Erwachsene in der Erstlinienbehandlung des met...</td>\n",
       "      <td>19.09.2019</td>\n",
       "      <td>PD-L1-Expression &lt; 50 %: Hinweis auf erheblich...</td>\n",
       "      <td>Pembrolizumab mit Carboplatin und Paclitaxel o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>A19-50</td>\n",
       "      <td>Erwachsene mit multiplem Myelom nach mind. ein...</td>\n",
       "      <td>16.09.2019</td>\n",
       "      <td>Wegen negativer Effekte bei mehreren Nebenwirk...</td>\n",
       "      <td>Pomalidomid mit Bortezomib und Dexamethason</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Anmerkung                                   Anwendungsgebiet       Datum  \\\n",
       "0    A19-52            Erwachsene mit Diabetes mellitus Typ 2   01.10.2019   \n",
       "1    A19-53            Erwachsene mit Diabetes mellitus Typ 2   01.10.2019   \n",
       "2    A19-61  Erwachsene in der Erstlinientherapie des metas...  19.09.2019   \n",
       "3    A19-62  Erwachsene in der Erstlinienbehandlung des met...  19.09.2019   \n",
       "4    A19-50  Erwachsene mit multiplem Myelom nach mind. ein...  16.09.2019   \n",
       "\n",
       "                                            Ergebnis  \\\n",
       "0  Zusatznutzen für keine der 3 vom G-BA benannte...   \n",
       "1  Zusatznutzen für keine der 5 vom G-BA benannte...   \n",
       "2  PD-L1-Expression < 50 %: für Frauen Beleg für ...   \n",
       "3  PD-L1-Expression < 50 %: Hinweis auf erheblich...   \n",
       "4  Wegen negativer Effekte bei mehreren Nebenwirk...   \n",
       "\n",
       "                                           Wirkstoff  \n",
       "0                            Dapagliflozin/Metformin  \n",
       "1                                      Dapagliflozin  \n",
       "2  Pembrolizumab mit Pemetrexed und Platin-Chemot...  \n",
       "3  Pembrolizumab mit Carboplatin und Paclitaxel o...  \n",
       "4       Pomalidomid mit Bortezomib und Dexamethason   "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "url = requests.get('https://www.iqwig.de/de/presse/amnog-uebersicht.7723.html')\n",
    "soup = BeautifulSoup(url.content,'lxml')\n",
    "\n",
    "trlist = soup.find_all(\"tr\")\n",
    "\n",
    "medis = []\n",
    "\n",
    "for element in trlist[1:]:\n",
    "    td_list = element.find_all('td')\n",
    "    datum = td_list[0].text\n",
    "    wirkstoff = td_list[1].text\n",
    "    anwendungsgebiet = td_list[2].text\n",
    "    ergebnis = td_list[3].text\n",
    "    anmerkung = td_list[4].text\n",
    "    \n",
    "    mini_dict = {\"Datum\": datum,\n",
    "        \"Wirkstoff\": wirkstoff,\n",
    "        \"Anwendungsgebiet\": anwendungsgebiet,\n",
    "        \"Ergebnis\": ergebnis,\n",
    "        \"Anmerkung\":anmerkung}\n",
    "    \n",
    "    medis.append(mini_dict)\n",
    "\n",
    "df = pd.DataFrame(medis)\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Anmerkung</th>\n",
       "      <th>Anwendungsgebiet</th>\n",
       "      <th>Datum</th>\n",
       "      <th>Ergebnis</th>\n",
       "      <th>Wirkstoff</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>A19-62</td>\n",
       "      <td>Erwachsene in der Erstlinienbehandlung des met...</td>\n",
       "      <td>19.09.2019</td>\n",
       "      <td>PD-L1-Expression &lt; 50 %: Hinweis auf erheblich...</td>\n",
       "      <td>Pembrolizumab mit Carboplatin und Paclitaxel o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>A19-49</td>\n",
       "      <td>Erwachsene mit Diabetes mellitus Typ 2, deren ...</td>\n",
       "      <td>02.09.2019</td>\n",
       "      <td>Mangels geeigneter Studiendaten Zusatznutzen n...</td>\n",
       "      <td>Empagliflozin / Linagliptin</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>A19-48</td>\n",
       "      <td>Erwachsene mit ALK-positivem, fortgeschrittene...</td>\n",
       "      <td>02.09.2019</td>\n",
       "      <td>Mangels geeigneter Studiendaten Zusatznutzen g...</td>\n",
       "      <td>Lorlatinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>A19-41</td>\n",
       "      <td>Erwachsene mit mittelschwerer bis schwerer Pla...</td>\n",
       "      <td>02.09.2019</td>\n",
       "      <td>Beleg für beträchtlichen Zusatznutzen bei Pati...</td>\n",
       "      <td>Risankizumab</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>A19-44</td>\n",
       "      <td>Migräneprophylaxe bei erwachsenen Patientinnen...</td>\n",
       "      <td>15.08.2019</td>\n",
       "      <td>Mangels geeigneter Studiendaten Zusatznutzen n...</td>\n",
       "      <td>Fremanezumab</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Anmerkung                                   Anwendungsgebiet       Datum  \\\n",
       "3    A19-62  Erwachsene in der Erstlinienbehandlung des met...  19.09.2019   \n",
       "5    A19-49  Erwachsene mit Diabetes mellitus Typ 2, deren ...  02.09.2019   \n",
       "6    A19-48  Erwachsene mit ALK-positivem, fortgeschrittene...  02.09.2019   \n",
       "7    A19-41  Erwachsene mit mittelschwerer bis schwerer Pla...  02.09.2019   \n",
       "9    A19-44  Migräneprophylaxe bei erwachsenen Patientinnen...  15.08.2019   \n",
       "\n",
       "                                            Ergebnis  \\\n",
       "3  PD-L1-Expression < 50 %: Hinweis auf erheblich...   \n",
       "5  Mangels geeigneter Studiendaten Zusatznutzen n...   \n",
       "6  Mangels geeigneter Studiendaten Zusatznutzen g...   \n",
       "7  Beleg für beträchtlichen Zusatznutzen bei Pati...   \n",
       "9  Mangels geeigneter Studiendaten Zusatznutzen n...   \n",
       "\n",
       "                                           Wirkstoff  \n",
       "3  Pembrolizumab mit Carboplatin und Paclitaxel o...  \n",
       "5                       Empagliflozin / Linagliptin   \n",
       "6                                         Lorlatinib  \n",
       "7                                      Risankizumab   \n",
       "9                                       Fremanezumab  "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['Ergebnis'].str.contains('nicht belegt')].head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Nivolumab                                                                                      4\n",
       "Lenvatinib                                                                                     3\n",
       "Lumacaftor / Ivacaftor                                                                         2\n",
       "Tofacitinib in Kombination mit Methotrexat                                                     2\n",
       "Atezolizumab                                                                                   2\n",
       "Dolutegravir                                                                                   2\n",
       "Tofacitinib                                                                                    2\n",
       "Rucaparib                                                                                      2\n",
       "Cariprazin                                                                                     2\n",
       "Daratumumab                                                                                    2\n",
       "Emicizumab                                                                                     2\n",
       "Pembrolizumab                                                                                  2\n",
       "Lorlatinib                                                                                     1\n",
       "Melatonin                                                                                      1\n",
       "Atezolizumab                                                                                   1\n",
       "Palbociclib in Kombination mit Fulvestrant                                                     1\n",
       "Damoctocog alfa pegol                                                                          1\n",
       "Axitinib                                                                                       1\n",
       "Sofosbuvir / Velpatasvir / Voxilaprevir                                                        1\n",
       "Lonoctocog alfa                                                                                1\n",
       "Osimertinib                                                                                    1\n",
       "Ipilimumab + Nivolumab                                                                         1\n",
       "Carfilzomib                                                                                    1\n",
       "Fluticasonfuroat / Umeclidinium / Vilanterol                                                   1\n",
       "Risankizumab                                                                                   1\n",
       "Saxagliptin/Metformin                                                                          1\n",
       "Lisdexamfetamin                                                                                1\n",
       "Glecaprevir / Pibrentasvir                                                                     1\n",
       "Dapagliflozin (Add-on zu Metformin)                                                            1\n",
       "Radium-223-dichlorid (Ra 223) als Monotherapie oder in Kombination mit einem LHRH-Analogon     1\n",
       "Benralizumab                                                                                   1\n",
       "Pembrolizumab mit Carboplatin und Paclitaxel oder nab-Paclitaxel                               1\n",
       "Cabozantinib                                                                                   1\n",
       "Ledipasvir/Sofosbuvir                                                                          1\n",
       "Pertuzumab                                                                                     1\n",
       "Dolutegravir / Rilpivirin                                                                      1\n",
       "Sofosbuvir (in Kombination mit Ribavirin)                                                      1\n",
       "Rolapitant                                                                                     1\n",
       "Elvitegravir / Cobicistat / Emtricitabin / Tenofoviralafenamid                                 1\n",
       "Glycopyrroniumbromid                                                                           1\n",
       "Etelcalcetid                                                                                   1\n",
       "Dimethylfumarat                                                                                1\n",
       "Tofacitinib                                                                                    1\n",
       "Reslizumab                                                                                     1\n",
       "Olaparib                                                                                       1\n",
       "Opicapon                                                                                       1\n",
       "Brodalumab                                                                                     1\n",
       "Dapagliflozin/Metformin (Fixkombination)                                                       1\n",
       "Enzalutamid                                                                                    1\n",
       "Dabrafenib                                                                                     1\n",
       "Elvitegravir / Cobicistat / Emtricitabin / Tenofovirdisoproxil                                 1\n",
       "Perampanel                                                                                     1\n",
       "Patiromer                                                                                      1\n",
       "Trifluridin/Tipiracil                                                                          1\n",
       "Macitentan                                                                                     1\n",
       "Abemaciclib mit Fulvestrant                                                                    1\n",
       "Fluticasonfuroat/Umeclidinium/Vilanterol                                                       1\n",
       "Bictegravir / Emtricitabin / Tenofoviralafenamid                                               1\n",
       "Ingenolmebutat                                                                                 1\n",
       "Ribociclib in Kombination mit  Aromatasehemmer oder Fulvestrant                                1\n",
       "Trametinib                                                                                     1\n",
       "Ipilimumab                                                                                     1\n",
       "Alectinib                                                                                      1\n",
       "Galcanezumab                                                                                   1\n",
       "Ertugliflozin / Sitagliptin (Diabetes mellitus Typ 2)                                          1\n",
       "Hydrocortison                                                                                  1\n",
       "Tildrakizumab                                                                                  1\n",
       "Dapagliflozin                                                                                  1\n",
       "Brivaracetam                                                                                   1\n",
       "Insulin degludec                                                                               1\n",
       "Insulin glargin / Lixisenatid in Kombination mit Metformin                                     1\n",
       "Pembrolizumab                                                                                  1\n",
       "Fingolimod                                                                                     1\n",
       "Erenumab                                                                                       1\n",
       "Vandetanib                                                                                     1\n",
       "Ixekizumab                                                                                     1\n",
       "Dacomitinib                                                                                    1\n",
       "Sonidegib                                                                                      1\n",
       "Sitagliptin in oraler Kombination mit Metformin                                                1\n",
       "Ceritinib                                                                                      1\n",
       "Ocrelizumab                                                                                    1\n",
       "Empagliflozin / Linagliptin                                                                    1\n",
       "Baricitinib                                                                                    1\n",
       "Sarilumab                                                                                      1\n",
       "Rurioctocog alfa pegol (Hämophilie A)                                                          1\n",
       "Abemaciclib mit Aromatasehemmer                                                                1\n",
       "Darunavir / Cobicistat / -Emtricitabin / -Tenofoviralafenamid                                  1\n",
       "Nonacog beta pegol                                                                             1\n",
       "Brigatinib                                                                                     1\n",
       "Fremanezumab                                                                                   1\n",
       "Mepolizumab                                                                                    1\n",
       "Name: Wirkstoff, dtype: int64"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['Ergebnis'].str.contains('nicht belegt')]['Wirkstoff'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
